Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
出版年份 2020 全文链接
标题
Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
作者
关键词
-
出版物
Cancers
Volume 12, Issue 8, Pages 2092
出版商
MDPI AG
发表日期
2020-07-30
DOI
10.3390/cancers12082092
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis
- (2020) Hannes Neuwirt et al. Cell Communication and Signaling
- Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor
- (2020) Marianne D. Sadar Expert Opinion on Drug Discovery
- A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics
- (2019) Phumvadee Wangtrakuldee et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Androgen receptor plasticity and its implications for prostate cancer therapy
- (2019) Oliver Snow et al. CANCER TREATMENT REVIEWS
- Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer
- (2019) Hille et al. Cells
- Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
- (2019) Meghan A. Rice et al. Frontiers in Oncology
- AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells
- (2018) Kshitij Verma et al. MOLECULAR CANCER THERAPEUTICS
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer
- (2017) Christof Bernemann et al. EUROPEAN UROLOGY
- Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review
- (2017) Trevor M. Penning EXPERT OPINION ON THERAPEUTIC PATENTS
- Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
- (2017) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC‑3 cells via an AKR1C3 mechanism
- (2017) Yoshitaka Sekine et al. Oncology Letters
- Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer
- (2016) Chengfei Liu et al. MOLECULAR CANCER THERAPEUTICS
- Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting
- (2016) E S Antonarakis et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells
- (2016) Martuza Sarwar et al. Oncotarget
- Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation
- (2016) Shao-Qian Sun et al. Oncotarget
- Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
- (2016) Julia Hoefer et al. Oncotarget
- Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
- (2016) Howard I. Scher et al. JAMA Oncology
- Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
- (2015) Jack Schalken et al. BJU INTERNATIONAL
- Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer
- (2015) C. Liu et al. CANCER RESEARCH
- mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity
- (2015) Federica Finetti et al. ENDOCRINE-RELATED CANCER
- Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
- (2015) Kush Dalal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Switching and withdrawing hormonal agents for castration-resistant prostate cancer
- (2015) David Lorente et al. Nature Reviews Urology
- AR-v7 protein expression is regulated by protein kinase and phosphatase
- (2015) Yinan Li et al. Oncotarget
- Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
- (2015) Bo Cao et al. Oncotarget
- AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression
- (2014) Yuantong Tian et al. Diagnostic Pathology
- Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor
- (2014) Huifang Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- An androgen receptor N-terminal domain antagonist for treating prostate cancer
- (2013) Jae-Kyung Myung et al. JOURNAL OF CLINICAL INVESTIGATION
- Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer
- (2013) Andy J. Liedtke et al. JOURNAL OF MEDICINAL CHEMISTRY
- AKR1C3 as a target in castrate resistant prostate cancer
- (2013) Adegoke O. Adeniji et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Unknown
- (2013) Agus Hamid et al. MOLECULAR MEDICINE
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- Neural protein gamma-synuclein interacting with androgen receptor promotes human prostate cancer progression
- (2012) Junyi Chen et al. BMC CANCER
- The androgen receptor gene mutations database: 2012 update
- (2012) Bruce Gottlieb et al. HUMAN MUTATION
- Selective Inhibition of Human Type-5 17β-Hydroxysteroid Dehydrogenase (AKR1C3) by Baccharin, a Component of Brazilian Propolis
- (2012) Satoshi Endo et al. JOURNAL OF NATURAL PRODUCTS
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Two New C-benzylated Dihydrochalcone Derivatives from the Leaves of Melodorum siamensis
- (2012) Uma Prawat et al. PLANTA MEDICA
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- (2011) C. Cai et al. CANCER RESEARCH
- Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening
- (2011) Daniela Schuster et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights
- (2010) Michael C. Byrns et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
- (2010) Karen E. Knudsen et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Novel Flufenamic Acid Analogues as Inhibitors of Androgen Receptor Mediated Transcription
- (2009) Clémentine Féau et al. ACS Chemical Biology
- AKR1C Isoforms Represent a Novel Cellular Target for Jasmonates alongside Their Mitochondrial-Mediated Effects
- (2009) N. J. Davies et al. CANCER RESEARCH
- A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth
- (2009) Z. Guo et al. CANCER RESEARCH
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Modulated expression of WFDC1 during carcinogenesis and cellular senescence
- (2008) Shalom Madar et al. CARCINOGENESIS
- AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids
- (2008) Lucie Škarydová et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer
- (2007) K Wako et al. JOURNAL OF CLINICAL PATHOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started